Reality stars hawk allergy drugs

Share this article:
Reality stars hawk allergy drugs
Reality stars hawk allergy drugs
Spring is in the air, and that means, well, sure, robins, daffodils, love and all that, but more importantly, campaigns for allergy drugs featuring endorsements by B-list celebrity sufferers.

This season's famous sneezers include soap star-turned-reality show host Alison Sweeney for McNeil Consumer's Zyrtec Liquid Gels and American Idol judge Kara DioGuardi for Merck's Claritin.

Sweeney, a longtime Days of Our Lives star and host of The Biggest Loser, took part in a Zyrtec event in which she raced six people in nose costumes. Dubbed “Race Against Your Allergies,” the stunt took place in New York City's Madison Square Park and delighted onlookers, including a few MM&M staffers.  

“With new Zyrtec Liquid Gels, people can get relief at liquid speed,” quipped McNeil VP marketing, upper respiratory Rohinish Hooda.

Meanwhile, DioGuardi is serving as the face of Claritin's Living Clear campaign, a user-generated content effort that invites users to submit a video to LivingClear.com showing what Claritin's non-drowsy formula has enabled them to do. Finalists will be announced May 6, and votes from visitors will decide the ultimate winner, who will pocket a $10,000 prize and win a chance to star in a Claritin online ad, while five finalists take home $1,000 and a one-year supply of Claritin products.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.